At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Terazosin 5 MG +1 moredrug
Likely dose
Terazosin 5 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Terazosin for Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating Terazosin 5 MG and Placebo oral capsule for Parkinson Disease. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
CollaboratorsUniversity of Iowa
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartSep 2019
Primary CompletionJun 2020
Study CompletionNov 2020
TodayJul 2026
First PostedApr 5, 2019
Enrollment StartSep 24, 2019
Primary CompletionJun 5, 2020
Study CompletionNov 18, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.2 years ago
Interventions
Terazosin 5 MGdrug
5 milligrams by mouth daily at bedtime
Placebo oral capsuledrug
1 capsule by mouth daily at bedtime